ArticleColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland2026
Metabolic syndrome and risk of advanced colorectal adenomas in a screening population: Frequentist and Bayesian analyses.
Article in Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundScreening colonoscopy prevents colorectal cancer (CRC) by detecting and removing premalignant lesions. Metabolic syndrome (MetS) has been proposed as an additional risk marker to refine risk stratification beyond age-based screening, but its independent association with advanced colorectal neoplasia remains uncertain.
methodsWe conducted a cross-sectional analysis of asymptomatic adults undergoing screening colonoscopy in the Salzburg Colon Cancer Prevention Initiative. Analyses were limited to participants with complete-case data for the Adult Treatment Panel III (ATP III) MetS definition (N = 4891). The primary endpoint was advanced colorectal lesions, defined as advanced adenoma and/or CRC. We estimated incidence rate ratios (IRR) using Poisson regression with robust variance in unadjusted, age/sex-adjusted and fully adjusted models (demographic and lifestyle covariates). Sensitivity analyses applied the International Diabetes Federation (IDF) MetS definition and insulin resistance (HOMA-IR; binary and per doubling). In an exploratory subsample, leptin (per doubling) was evaluated, including joint models with MetS. Bayesian models (non-informative, pessimistic, sceptical priors) quantified posterior effect distributions and equivalence probabilities.
resultsAdvanced lesions occurred in 389/4891 participants (7.95%) and were more frequent in ATP III MetS (9.66% vs. 6.97%; p = 0.001). In frequentist analyses, ATP III MetS was associated with advanced lesions in unadjusted models (IRR: 1.39; 95% CI, 1.15-1.68) but not after age/sex adjustment (IRR: 1.09; 95% CI, 0.90-1.32) or full adjustment (IRR: 1.06; 95% CI, 0.83-1.36). Age was the dominant predictor (fully adjusted IRR: 1.73 per decade; 95% CI, 1.53-1.95), while female sex was protective (IRR: 0.57; 95% CI, 0.44-0.73). Findings were concordant using the IDF definition (unadjusted IRR: 1.39; age/sex-adjusted 1.09; fully adjusted 1.07) and for HOMA-IR (binary: no association; per doubling: unadjusted IRR: 1.10, p = 0.052; adjusted null). In the leptin subsample (N = 602), leptin was not independently associated with advanced lesions (per doubling IRR: 0.85 unadjusted; 0.96 age/sex-adjusted; 0.95 fully adjusted) and did not materially alter MetS estimates. Bayesian analyses mirrored attenuation with adjustment; in fully adjusted models, sceptical priors yielded a posterior median IRR of 1.01 (95% CrI: 0.91-1.12) with a 92.9% probability that the MetS effect lay within ±10% of no effect.
conclusionsThe apparent excess risk of advanced colorectal lesions in MetS is explained by age and sex. Across MetS definitions, HOMA-IR, leptin and Bayesian sensitivity analyses, MetS does not provide independent incremental information for CRC screening risk stratification beyond established demographic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.